Correlation between PGC-1α gene polymorphism and metabolic diseases

doi:10.12092/j.issn.1009-2501.2019.10.014

Abstract

Abstract:

Peroxisome proliferator-activated receptor gamma coactivator 1-alpha（PGC-1α）is an important nuclear transcriptional coactivator in human body. Nuclear receptors and transcription factors interact to regulate the expression of their target genes. PGC1-α plays an important role in human energy metabolism, which is involved in fatty acid oxidation, hepatic gluconeogenesis and regulation of mitochondrial ATP biosynthesis.Studies have shown that PGC-1α gene polymorphism is closely related to the occurrence of metabolic diseases such as type 2 diabetes, diabetic nephropathy, obesity and coronary heart disease. Exploring the correlation between PGC-1α gene polymorphism and metabolic diseases is beneficial to detect and evaluate the risk of metabolic diseases from the genetic level, so as to realize early detection and prevention of the disease, improve the quality of life of metabolic diseases, and prolong Survival period. This article reviews the research progress of the metabolic pathways involved in PGC-1α and the correlation between its genetic polymorphisms and metabolic diseases in the recent five years.

Key words: peroxisome proliferator-activated receptor gamma coactivator 1-alpha, metabolism, gene polymorphism

CLC Number:

R968
R589

FAN Zhipeng, LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, HAO Zhuowen, SUN Gongpeng, DONG Li, YUE Jiang, WU Jianguo, YE Qifa. Correlation between PGC-1α gene polymorphism and metabolic diseases[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1172-1180.

References

［1］ Wang X, Wen F, Hong T, et al. The research progress of peroxisome proliferator activated receptor γ coactivator 1α［J］. Int J Pathol Clin Med, 2012, 32(1):45-49.
［2］Handschin C, Spiegelman BM.Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators energy homeostasis and metabolis［J］. Endocrinol Rev, 2006, 27(7):728-735.
［3］Liu C, Lin JD.PGC-1 coactivators in the control of energy metabolism［J］. Acta Biochim Biophys Sin (Shanghai), 2011, 43(4):248-257.
［4］闫春雷，黄欣，苏乐群，等. PGC-1α的转录调节和翻译后修饰［J］. 中国生物化学与分子生物学报，2015，1（1）：12-19.
［5］Lee J, Salazar Hernández MA, Auen T, et al. PGC-1α functions as a co-suppressor of XBP1s to regulate glucose metabolism ［J］. Mol Metab, 2018, 7:119-131.
［6］Tavares CD, Sharabi K, Dominy JE, et al. The methionine transamination pathway controls hepatic glucose metabolism through regulation of the GCN5 acetyltransferase and the PGC-1αtranscriptional coactivator［J］. J Biol Chem, 2016, 291(20):10635-10645.
［7］Hatazawa Y, Qian K. PGC-1α regulates alanine metabolism in muscle cells［J］. PLoS One, 2018, 13(1): e0190904.
［8］Yao L, Cui X, Chen Q, et al. Cold-Inducible SIRT6 regulates thermogenesis of brown and beige fat［J］. Cell Rep, 2017, 20(3): 641-654.
［9］Crisol BM, Veiga CB, Lenhare L, et al.Nicotinamide riboside induces a thermogenic response in lean mice［J］. Life Sci, 2018, 211:1-7.
［10］Zhang X, Zhang QX, Wang X, et al. Dietary luteolin activates browning and thermogenesis in mice through an AMPK/PGC-1αpathway-mediated mechanism［J］.Int J Obes (Lond), 2016, 40(12): 1841-1849.
［11］Gill JA, La Merrill MA.An emerging role for epigenetic regulation of PGC-1α expression in environmentally stimulated brown adipose thermogenesis［J］. Environ Epigenet, 2017, 3(2): dvx009.
［12］Villena JA. New insights into PGC-1 coactivators: redefining their role in the regulation of mitochondrial function and beyond［J］. FEBS J, 2015, 282(4): 647-672.
［13］Fang He, Jie-Qiong Jin, Qing-Qing Qin, et al.Resistin regulates fatty acid β oxidation by suppressing expression of peroxisome proliferator activator receptor gamma-coactivator 1α (PGC-1α)［J］.Cell Physiol Biochem, 2018, 46(5): 2165-2172.
［14］Do AR, Cho SJ, Cho YY, et al. Antiobesity effects of short-chain chitosan in diet-induced obese mice［J］. J Med Food, 2018, 21(9): 927-934.
［15］Mehlem A, Palombo I, Wang X, et al. PGC-1α coordinates mitochondrial respiratory capacity and muscular fatty acid uptake via regulation of VEGF-B［J］. Diabetes, 2016, 65(4): 861-873.
［16］Masuda I, Koike M, Nakashima S, et al. Apple procyanidins promote mitochondrial biogenesis and proteoglycan biosynthesis in chondrocytes［J］. Sci Rep, 2018, 8(1): 7229.
［17］Saihara K, Kamikubo R, Akagawa M, et al. Pyrroloquinoline quinone, a redox-active o-quinone, stimulates mitochondrial biogenesis by activating the SIRT1/PGC-1α signaling pathway［J］. Biochemistry, 2017, 56(50):6615-6625.
［18］Shokouhi S, Haghani K, Borji P, et al. Association between PGC-1alpha gene polymorphisms and type 2 diabetes risk: a case-control study of an Iranian population［J］.Can J Diabetes, 2015, 39(1): 65-72.
［19］Jemaa Z, Kallel A, Sleimi C, et al.The Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is associated with type 2 diabetes in Tunisian population［J］. Diabetes Metab Syndr, 2015, 9(4): 316-319.
［20］邓德耀，袁文丽，金鑫鑫，等. PGC-1α基因GIy482Ser多态性与2型糖尿病的相关性研究［J］. 昆明医科大学学报，2014,35（3）：28-31.
［21］Park S, Kang S, Kim BC, et al. Interaction effect of PGC-1α rs10517030 variants and energy intake in the risk of type 2 diabetes in middle-aged adults［J］. Eur J Clin Nutr, 2017, 71(12): 1442-1448.
［22］孙亮，王松岚，孙宏，等. 北京地区汉族人群PPARGCIA基因启动子变异筛查及与2型糖尿病的关联研究［J］. 中华医学遗传学杂志，2014,31（3）：352-356.
［23］Yang Y, Mo X, Chen S, et al. Association of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PPARGC1A) gene polymorphisms and type 2 diabetes mellitus: a meta-analysis［J］. Diabetes Metab Res Rev, 2011, 27(2): 177-184.
［24］Song J, Liu YY, Long Y, et al. PPARGC1A gene Thr394Thr G/A polymorphism and its association with type 2 diabetes mellitus and insulin resistance in a Chinese population［J］. Zhonghua Yi Xue Yi Chuan Xue Za Zhi，2010, 27(5): 550-553.
［25］Zhu L, Huang Q, Xie Z, et al. PPARGC1A rs3736265 G>A polymorphism is associated with decreased risk of type 2 diabetes mellitus and fasting plasma glucose level［J］. Oncotarget, 2017, 8(23): 37308-37320.
［26］Vandenbeek R, Khan NP, Estall JL, et al.Linking Metabolic Disease With the PGC-1α Gly482Ser polymorphism［J］. Endocrinology, 2018, 159(2): 853-865.
［27］Weng SW, Lin TK, Wang PW, et al.Gly482Ser polymorphism in the peroxisome proliferator-activated receptor gamma coactivator-1alpha gene is associated with oxidative stress and abdominal obesity［J］. Metabolism, 2010, 59(4): 581-586.
［28］Vázquez-Del Mercado M, Guzmán-Ornelas MO, Corona Meraz FI, et al.The 482Ser of PPARGC1A and 12Pro of PPARG2 alleles are associated with reduction of metabolic risk factors even obesity in a mexican-mestizo population［J］. Biomed Res Int, 2015, 2015: 285491.
［29］Vimaleswaran KS, Radha V, Anjana M, et al.Effect of polymorphisms in the PPARGC1A gene on body fat in Asian Indians［J］. Int J Obes (Lond), 2006, 30(6): 884-891.
［30］Zamaninour N, Mirzaei K, Maghbooli Z, et al.Peroxisome proliferator-activated receptor gamma coactivator-1α variation: a closer look at obesity onset age and its related metabolic status and body composition［J］. Appl Physiol Nutr Metab, 2018,43(12):1321-1325.
［31］Petrovic MG, Kunej T, Peterlin B, et al.Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-gamma coactivator-1 gene might be a risk factor for diabetic retinopathy in slovene population (Caucasians) with type 2 diabetes and the Pro12Ala polymorphism of the PPARgamma gene is not［J］. Diabetes Metab Res Rev, 2005, 21(5): 470-474.
［32］Gayathri SB, Radha V, Vimaleswaran KS, et al. Association of the PPARGC1A gene polymorphism with diabetic nephropathy in an Asian Indian population (CURES-41)［J］. Metab Syndr Relat Disord, 2010, 8(2): 119-126.
［33］李岑，杨驭媒. PGC-1α基因多态性与冠心病的相关性分析［J］. 医学检验与临床，2012,23（1）：7-9.
［34］张燕，徐伟伟，陈琪，等. 中国江苏地区汉族人群过氧化体增殖物激活型受体γ辅激活因子1α基因多态性与冠心病相关性［J］. 中国动脉硬化杂志，2007，7:546.
［35］Yongsakulchai P, Settasatian C, Settasatian N, et al.Association of combined genetic variations in PPARγ, PGC-1α, and LXRα with coronary artery disease and severity in Thai population［J］. Atherosclerosis, 2016, 248: 140-148.
［36］Lin YC, Chang PF, Chang MH, et al. A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children［J］. Am J Clin Nutr, 2013, 97(2): 326-331.
［37］Tai CM, Huang CK, Tu HP, et al. Interactions of a PPARGC1A variant and a PNPLA3 variant affect nonalcoholic steatohepatitis in severely obese taiwanese patients［J］. Medicine (Baltimore), 2016, 95(12): e3120.
［38］Yoneda M, Hotta K, Nozaki Y, et al.Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)［J］. BMC Gastroenterol, 2008, 8:27.
［39］Shivaswamy V, Boerner B, Larsen J.Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes［J］. Endocr Rev, 2016, 37(1): 37-61.
［40］Ouyang Meng, Xin Huawen, Tang Xia, et al. Ressearch on risk factors of adverse reactions caused by tacrolomus in renal transplant recipients［J］. Chinese pharmacist, 2016, 19(5):892-895.
［41］李彩霞，卢慧娟，徐建鸣，等. 肝移植术后代谢并发症危险因素及管理措施的研究进展［J］. 护理研究，2017,31（20）：2433-2436.
［42］Li Lu, Chen Huizhen, Liang Xingguang, et al. Research and treatment progress on post-transplantation diabetes mellitus caused by tacrolimus［J］. Chin J Transplant, 2017, 11(1):44-49.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[3]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[4]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[5]	WANG Siyu, LI Jiawei, LI Chenghao, LI Ling, GUO Qingyang, QIU Lu, ZHOU Shiqin, LIU Yongqi. Research progress of lactate dehydrogenase A in digestive system tumors and related drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 445-454.
[6]	CAI Zuhuan, DENG Taomei, WEI Naijie, ZHU Dan, QIAN Fei, WANG Guangji, ZHANG Jingwei. Silybin ameliorates lipid metabolism disorders in mice with non-alco-holic steatohepatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 241-248.
[7]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[8]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[9]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[10]	LIU Yizhen, REN Lingxuan, YANG Jianjun, HE Jianyu, LIU Xiaojun, WANG Long, LIN Rong. Study on the screening of active constituents of Taohong Siwu Decoction and the protective effect of ferulic acid on myocardial injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 505-515.
[11]	DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
[12]	WEI Jifang, YUE Hongmei, LIU Nanyu, SONG Peipei, XIE Yingying, WANG Jiaqi, WEI Yaqian. Research progress on the relationship between thyroid hormone and idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 307-313.
[13]	DU Chen, TIAN He, CAO Yang, WANG Yongjun, ZHANG Yan. Research progress on bone metabolism disorders associated with PCOS elucidated from endocrine hormones [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 328-333.
[14]	ZHANG Liang, LIAO Yongqun, XIA Qinchuan, ZHOU Shitong, LI Xiaoli. Ferroptosis regulatory signaling pathway and its research progress in related diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 227-234.
[15]	CHEN Yu, GU Bing, LI Huanan. Modulating gut miocrobiota: a new strategy in the treatment of gout [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1307-1314.